01 — At a Glance
The Amine King With a Structural Headache
- Q3 FY26 Revenue₹336 Cr
- Q3 FY26 PAT₹30.76 Cr
- Q3 FY26 EPS₹9.49
- Annualised EPS (Q3×4)₹37.96
- 9M FY26 PAT YoY-11.65%
- Book Value₹581
- Price to Book1.81x
- 52-Week High/Low₹1,946 / ₹905
- 1-Year Return-18.8%
- 3-Year CAGR Return-20.2%
⚠️ Reality Check: Balaji Amines is the largest maker of aliphatic amines in India, commanding ~50% market share. Then China dumped 10,000 tonnes of ethylene diamine at discount prices. The company’s subsidiary BSCL collapsed from ₹3,000 Cr revenue in FY24 to ₹1,306 Cr in FY25. Now ammonia supply from Middle East (where 70% of India’s imported ammonia comes from) is disrupted by geopolitical tensions. Meanwhile the stock is down 18.8% in one year. Investors are learning that being the market leader in a commodity doesn’t make you immune to commodity volatility. Shocking? Absolutely not.
02 — Introduction
Where Amine Molecules Go to Party (And Get Overproduced)
Balaji Amines Limited is a company that makes chemicals most people will never know the name of, yet they’re embedded in literally everything you touch. Methylamines, ethylamines, dimethylformamide, acetonitrile — these are the unsung heroes of pharma, agrochemicals, dyes, paints, rubber, and animal feed. If a product needed a solvent or chemical intermediate, Balaji Amines either made it or was thinking about making it.
The company started in 1988 and has grown into a ₹3,386 crore market cap behemoth. It operates four manufacturing units (three in Solapur, one in Hyderabad) with an installed capacity of 2,92,000 MTPA. It also owns 55% of Balaji Speciality Chemicals Ltd, which manufactures ethylene diamine (EDA), piperazine, and other specialty derivatives. The product portfolio spans over 40 different offerings, and management prides itself on being “an exclusive manufacturer of a range of specialty chemicals” for which — theoretically — competition should be limited.
Theoretically. Then reality showed up, and China sent 10,000 tonnes of EDA at ₹4 per kg when Balaji was selling at ₹8. The company’s ROCE fell from 16% in FY24 to 11% in FY25. The subsidiary BSCL’s revenue fell 57%. The company was rated Negative by Ind-Ra in June 2025. And now, March 2026, ammonia supplies are being disrupted from the Middle East. This is a company fighting multiple fires at once.
From the Jan 2026 Concall: Management said “capacities will ramp-up gradually over FY26-FY27” and they’re “targeting different industries through product diversification.” Translation: We’re hoping demand recovers faster than our new plants come online. Also, we’re building a 20 MW solar plant, which will help margins. When it’s commissioned. If weather cooperates.
03 — Business Model: WTF Do They Even Do?
They Make Invisible Chemicals That Are Very Visible To Your Accountant’s Pain
Balaji Amines’ business model is deceptively simple: buy raw materials (ammonia, methanol, ethylene), run them through four state-of-the-art plants with DCS technology, and sell the resulting amines and derivatives to end-customers in pharma, agro, paints, rubber, and water treatment. Revenue splits: Pharma (51%), Agrochemicals (26%), Paints & Resins (4%), and everything else (19%). Exports account for ~13% of revenue, spanning 50+ countries including US, UK, Europe, and Asia.
The problem is that these markets are intensely cyclical. Pharma demand fluctuates with drug development cycles. Agrochem demand follows monsoon patterns and government policy. Paints and dyes follow real estate and industrial sentiment. And all of these markets are now facing Chinese competition at dumping prices. The company’s installed capacity is 2,92,000 MTPA, but capacity utilization has been under 70% for years — a sign that supply is outpacing demand across the board.
FY25 was a disaster: consolidated revenue fell 14% YoY to ₹1,389 Cr. EBITDA margin compressed from 20% to 17%. Standalone PAT fell 32% YoY. The subsidiary BSCL saw revenue crater 57% from ₹3,004 Cr to ₹1,306 Cr, primarily due to oversupply of EDA from China and weak demand for piperazine. On the positive side: the company is still generating ₹2,554 Cr in operating cash flow (FY25), which means it can fund capex internally and keep dividends alive.
Pharma Segment51%Revenue Mix
Agrochem Segment26%Revenue Mix
Installed Capacity292KMTPA
Capex (FY26-27)₹2,000 CrPlanned
The Capex Gamble: Management is planning ₹2,000 Cr capex in both FY26 and FY27 to commission new plants: DME (100,000 TPA), NMM (5,000 TPA), Acetonitrile upgrade (9,000 TPA additional), and a ₹750 Cr greenfield at BSCL for HCN, NaCN, and EDTA. All this while BSCL is bleeding out and capacity utilization is in the 60–70% range. The hope? Import substitution + product mix shift + supply constraints in China = higher demand. The risk? China figures out how to run their plants at -10% margins too, and India is left holding ₹2,000 Cr in capex cost.
💬 Would you invest in massive capex when your subsidiary’s revenue dropped 57% YoY and your main product (EDA) is being dumped by China? Or is Balaji management playing 4D chess that the rest of us can’t see?
04 — Financials Overview: Q3 FY26
The Numbers That Made Investors Squirm
Result type: Quarterly Results (Q3 FY26) | Q3 FY26 EPS: ₹9.49 | Annualised EPS (Q3×4): ₹37.96 | Full-year FY25 EPS: ₹44.50
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 336 | 321 | 348 | +4.9% | -3.3% |
| EBITDA | 62 | 54 | 67 | +15.1% | -7.8% |
| EBITDA Margin % | 18.3% | 16.7% | 19.2% | +160 bps | -90 bps |
| PAT | 31 | 31 | 37 | -1.2% | -17.1% |
| EPS (₹) | 9.49 | 10.24 | 10.67 | -7.3% | -11.1% |
What the Numbers Tell You: Q3 FY26 consolidated revenue ₹336 Cr — up 4.9% YoY but down 3.3% QoQ. EBITDA up 15.1% YoY, which is encouraging. But PAT down 1.2% YoY and 17.1% QoQ because interest and tax expenses remained flat. The real story: volumes were maintained (25,894 MT vs 24,097 MT in Q3 FY25), but pricing remains under pressure. EBITDA margins improved YoY but compressed QoQ. This is a company caught between capacity additions (which require capex that hits cash flow) and weak demand (which prevents pricing power). The P/E at 23.5x against a full-year FY25 EPS of ₹44.50 looks stretched given that annualized Q3 EPS is only ₹37.96. Investors are betting on a demand recovery. The stock is betting they’re right.
05 — Valuation: The Fair Value Trap
Is It Cheap, Or Just Getting Cheaper?
Method 1: P/E Based
FY25 EPS = ₹44.50. Q3 annualized EPS = ₹37.96. Specialty chemicals industry median P/E = ~18–22x. Balaji at 23.5x trades at a 7–30% premium. Given the weak ROCE (11%), ongoing capacity underutilization (65%), and negative rating outlook from Ind-Ra, a multiple compression seems warranted. Fair P/E band: 16x–21x.
Range: ₹607 – ₹934
Method 2: EV/EBITDA Based
FY25 EBITDA = ₹232 Cr (standalone). Consolidated EBITDA ₹265 Cr. Current EV = ₹3,231 Cr (market cap minus net cash). EV/EBITDA = 12.4x. Specialty chemicals typically trade at 10x–14x. Given the Ind-Ra downgrade (Negative outlook), a 10x–12x multiple seems appropriate.
EV range (10x–12x): ₹2,650 Cr – ₹3,180 Cr → Per share:
Range: ₹783 – ₹936
Method 3: DCF Based
Base FCF: ₹255 Cr (FY25 operating CF). Growth: 4–6% for 5 years (conservative given headwinds). Terminal growth: 2.5%. WACC: 10.5%.
→ PV of 5-year FCFs at 10.5%: ~₹1,450 Cr
→ Terminal Value (2.5% growth / 8% cap rate): ~₹2,980 Cr
→ Total EV: ~₹4,430 Cr (net cash ₹500 Cr)
Range: ₹738 – ₹923
Fair Value Range: ₹607 – ₹936
Current Price: ₹1,045 | Price-to-Fair: 1.12x overvalued
⚠️ EduInvesting Fair Value Range: ₹607 – ₹936. CMP ₹1,045 sits 12% above the fair value range. This fair value assessment assumes flat-to-modest growth, moderate capex execution, and demand recovery in FY27. If capex delays extend beyond FY27 or Chinese dumping persists, downside risk to ₹500–550 exists. This is for educational purposes only and is not investment advice. Please consult a SEBI-registered investment advisor before making decisions.
06 — What’s Cooking: News, Triggers & Drama
When Your Business Gets Hit By Geopolitical Whiplash
